CoChat

Immunologically Active Cardiac Fibroblasts Expressing Major Histocompatibility Complex-II Promote Doxorubicin Cardiotoxicity

Zambrano, Maria A., Bayer, Abraham L., Ramos, Ramon B., Stortini, Constanza, Kaur, Kuljeet, Bedi, Kenneth, Margulies, Kenneth B., Alcaide, Pilar · 2026 · The American Journal of Pathology
Cited by 0

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajpath.2026.08.007

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 44

  1. Gewirtz, 1999, A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin, Biochem Pharmacol, 57, 727, 10.1016/S0006-2952(98)00307-4 · DOI · Paper page
  2. Wang, 2004, Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms: intermediacy of H(2)O(2)- and p53-dependent pathways, J Biol Chem, 279, 25535, 10.1074/jbc.M400944200 · DOI · Paper page
  3. Linders, 2024, A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging, NPJ Aging, 10, 9, 10.1038/s41514-024-00135-7 · DOI · Paper page
  4. Suzuki, 1979, Cardiotoxicity of anthracycline antineoplastic drugs--clinicopathological and experimental studies, Jpn Circ J, 43, 1000, 10.1253/jcj.43.1000 · doi:10.1253/jcj.43.1000
  5. Zamorano, 2017, 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC), Eur J Heart Fail, 19, 9, 10.1002/ejhf.654 · DOI · Paper page
  6. Willis, 2019, Doxorubicin exposure causes subacute cardiac atrophy dependent on the striated muscle-specific ubiquitin ligase MuRF1, Circ Heart Fail, 12, 10.1161/CIRCHEARTFAILURE.118.005234 · DOI
  7. Jordan, 2018, Left ventricular mass change after anthracycline chemotherapy, Circ Heart Fail, 11, 10.1161/CIRCHEARTFAILURE.117.004560 · DOI
  8. Neilan, 2012, Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines, Am J Cardiol, 110, 1679, 10.1016/j.amjcard.2012.07.040 · DOI · Paper page
  9. Young, 1981, The anthracycline antineoplastic drugs, N Engl J Med, 305, 139, 10.1056/NEJM198107163050305 · DOI · Paper page
  10. Bayer, 2024, Cytotoxic T cells drive doxorubicin-induced cardiac fibrosis and systolic dysfunction, Nat Cardiovasc Res, 3, 970, 10.1038/s44161-024-00507-y · DOI
  11. Borowiec, 2025, Interleukin-6 in anthracycline-related cardiac dysfunction: a comparison with myeloperoxidase and TNF-alpha, Int J Mol Sci, 26, 4071, 10.3390/ijms26094071 · doi:10.3390/ijms26094071
  12. Farbehi, 2019, Single-cell expression profiling reveals dynamic flux of cardiac stromal, vascular and immune cells in health and injury, Elife, 8, 10.7554/eLife.43882 · DOI · Paper page
  13. Kanisicak, 2016, Genetic lineage tracing defines myofibroblast origin and function in the injured heart, Nat Commun, 7, 10.1038/ncomms12260 · DOI · Paper page
  14. Zeigler, 2016, Computational modeling of cardiac fibroblasts and fibrosis, J Mol Cell Cardiol, 93, 73, 10.1016/j.yjmcc.2015.11.020 · DOI · Paper page
  15. Molkentin, 2017, Fibroblast-specific genetic manipulation of p38 mitogen-activated protein kinase in vivo reveals its central regulatory role in fibrosis, Circulation, 136, 549, 10.1161/CIRCULATIONAHA.116.026238 · DOI · Paper page
  16. Litvinukova, 2020, Cells of the adult human heart, Nature, 588, 466, 10.1038/s41586-020-2797-4 · DOI · Paper page
  17. Ren, 2020, Single-cell reconstruction of progression trajectory reveals intervention principles in pathological cardiac hypertrophy, Circulation, 141, 1704, 10.1161/CIRCULATIONAHA.119.043053 · DOI · Paper page
  18. Wang, 2020, Single-cell reconstruction of the adult human heart during heart failure and recovery reveals the cellular landscape underlying cardiac function, Nat Cell Biol, 22, 108, 10.1038/s41556-019-0446-7 · DOI · Paper page
  19. Sumida, 2024, The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases, Nat Rev Immunol, 24, 503, 10.1038/s41577-024-00994-x · DOI · Paper page
  20. Ngwenyama, 2022, Antigen presentation by cardiac fibroblasts promotes cardiac dysfunction, Nat Cardiovasc Res, 1, 761, 10.1038/s44161-022-00116-7 · DOI · Paper page
  21. Nevers, 2015, Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure, Circ Heart Fail, 8, 776, 10.1161/CIRCHEARTFAILURE.115.002225 · DOI · Paper page
  22. Nevers, 2017, Th1 effector T cells selectively orchestrate cardiac fibrosis in nonischemic heart failure, J Exp Med, 214, 3311, 10.1084/jem.20161791 · DOI · Paper page
  23. Bayer, 2026, STING promotes CD8 T-cell cardiotropism and fibrosis from distinct cellular compartments in doxorubicin cardiomyopathy, Cardiovasc Res, 122, 1224, 10.1093/cvr/cvag098 · DOI · Paper page
  24. Guo, 2025, Human single-nucleus RNA sequencing identifies CD47 as a therapeutic target for doxorubicin-induced cardiomyopathy, Circulation, 152, 661, 10.1161/CIRCULATIONAHA.124.071217 · DOI
  25. Johansen, 2025, Transcription factor 21 regulates cardiac myofibroblast formation and fibrosis, Circ Res, 136, 44, 10.1161/CIRCRESAHA.124.325527 · DOI
  26. Trempus, 2023, Functional Pdgfra fibroblast heterogeneity in normal and fibrotic mouse lung, JCI Insight, 8, 10.1172/jci.insight.164380 · DOI
  27. Vivier, 2011, Innate or adaptive immunity? the example of natural killer cells, Science, 331, 44, 10.1126/science.1198687 · DOI · Paper page
  28. Zimmer, 2005, Clinical and immunological aspects of HLA class I deficiency, QJM, 98, 719, 10.1093/qjmed/hci112 · DOI · Paper page
  29. Ma, 2020, Temporary blockade of interferon-gamma ameliorates doxorubicin-induced cardiotoxicity without influencing the anti-tumor effect, Biomed Pharmacother, 130, 10.1016/j.biopha.2020.110587 · DOI
  30. Abe, 2022, Doxorubicin causes ferroptosis and cardiotoxicity by intercalating into mitochondrial DNA and disrupting Alas1-dependent heme synthesis, Sci Signal, 15, 10.1126/scisignal.abn8017 · DOI
  31. Christidi, 2021, Regulated cell death pathways in doxorubicin-induced cardiotoxicity, Cell Death Dis, 12, 339, 10.1038/s41419-021-03614-x · DOI · Paper page
  32. Buttmann, 2007, Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells, J Vasc Res, 44, 51, 10.1159/000097977 · DOI
  33. Rudick, 1996, Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis, Ann Neurol, 40, 618, 10.1002/ana.410400412 · DOI · Paper page
  34. Lei, 2023, Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity, Cell, 186, 3013, 10.1016/j.cell.2023.05.039 · DOI · Paper page
  35. Osataphan, 2020, Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: insights for future interventions, J Cell Mol Med, 24, 6534, 10.1111/jcmm.15305 · DOI
  36. Zhou, 2001, Doxorubicin-induced persistent oxidative stress to cardiac myocytes, Toxicol Lett, 121, 151, 10.1016/S0378-4274(01)00329-0 · DOI · Paper page
  37. Diaz, 2024, Sex differences in the development of anthracycline-associated heart failure, J Card Fail, 30, 907, 10.1016/j.cardfail.2023.10.477 · DOI
  38. Su, 2024, Sex differences in doxorubicin-induced cardiotoxicity: insights from transcriptome analysis, Adv Therap, 7, 10.1002/adtp.202400036 · DOI
  39. Blum, 2021, Sex and tamoxifen confound murine experimental studies in cardiovascular tissue engineering, Sci Rep, 11, 8037, 10.1038/s41598-021-87006-3 · DOI
  40. Perrino, 2021, Improving translational research in sex-specific effects of comorbidities and risk factors in ischaemic heart disease and cardioprotection: position paper and recommendations of the ESC Working Group on Cellular Biology of the Heart, Cardiovasc Res, 117, 367, 10.1093/cvr/cvaa155 · DOI
  41. Asnani, 2018, Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity, JCI Insight, 3, 10.1172/jci.insight.96753 · DOI
  42. Twelves, 1991, Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer, Cancer Chemother Pharmacol, 28, 302, 10.1007/BF00685539 · doi:10.1007/bf00685539
  43. Zhu, 2009, Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway, Circulation, 119, 99, 10.1161/CIRCULATIONAHA.108.799700 · DOI · Paper page
  44. Wielgat, 2023, Tamoxifen modulates the immune landscape of the tumour microenvironment: the paired siglec-5/14 checkpoint in anti-tumour immunity in an in vitro model of breast cancer, Int J Mol Sci, 24, 5512, 10.3390/ijms24065512 · DOI

Metadata

Authors
Zambrano, M. A., Bayer, A. L., Ramos, R. B., Stortini, C., Kaur, K., Bedi, K., Margulies, K. B., & Alcaide, P.
Venue
The American Journal of Pathology
Publisher
Elsevier BV
Published
2026-09
ISSN
0002-9440
Cited by
0
References
3
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
National Heart Lung and Blood Institute Division of Intramural Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.